Surai Jones

发表

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

Manish R. Patel, R. Advani, A. Hagenbeek, 2015, The Lancet. Oncology.

Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

R. Advani, B. Cheson, A. Goy, 2016, Clinical Cancer Research.

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).

A. Hagenbeek, G. Salles, L. Sehn, 2019, The Lancet. Haematology.

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

I. Flinn, T. Phillips, O. Press, 2016 .

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

G. Salles, K. Kolibaba, H. Tilly, 2016 .

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

T. Wilson, D. Juric, Matthew T. Chang, 2020, Clinical Cancer Research.

Sexual violence, posttraumatic stress disorder, and the pelvic examination: how do beliefs about the safety, necessity, and utility of the examination influence patient experiences?

R. Moos, D. Spiegel, J. Finney, 2010, Journal of women's health.

Distress and Pain During Pelvic Examinations: Effect of Sexual Violence

A. Thrailkill, J. Finney, J. Ruzek, 2008, Obstetrics and gynecology.

Receipt of cervical cancer screening in female veterans: impact of posttraumatic stress disorder and depression.

R. Moos, G. Sawaya, J. Finney, 2013, Women's health issues.

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

P. Ascierto, A. Ribas, C. Garbe, 2021, Clinical Cancer Research.

Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Jeffrey A Jones, J. Gribben, I. Flinn, 2017 .

Abstract CT046: A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) inPIK3CA-mutated locally advanced or metastatic solid tumors

J. Baselga, T. Wilson, D. Juric, 2018, Clinical Trials.

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

R. Advani, A. Hagenbeek, G. Salles, 2014 .

Changes in Depressive Symptoms and Impact on Treatment Course Among Hepatitis C Patients Undergoing Interferon-α and Ribavirin Therapy: A Prospective Evaluation

Megan Oser, J. Chapman, J. Weitlauf, 2011, The American Journal of Gastroenterology.